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Only a few thousand people worldwide are diagnosed 
each  year  of  Acute  Promyelocytic  Leukemia  (APL). 
However, for a number of reasons, such rare disease is 
regarded as a paradigm in the entire field of medicine. 
Once considered the most malignant human leuk
as well as the one associated with the worst prognosis, 
APL has been transformed in the past few decades into 
the  most  frequently  curable  one.  This  extraordinary 
progress  has  been  the  result  of  an  unprecedented 
coincidence of advances in both biologic
research.  Today,  APL  represents  a  model  for  i) 
differentiation therapy, ii) tailored treatment targeting a 
molecular  aberration,  iii)  value  of  minimal  residual 
disease assessment as a surrogate of clinical outcome, 
and  iv)  translational  research  in  general.  In  the 
following  pages  are  reviewed  the  major  discoveries 
and  achievements  in  APL biology and  therapy, with 
particular emphasis on those that have had more direct 
an  impact  in  patient  outcome.  Finally,  we  briefly 
discuss  some  of  the  unsolved  issues  and  future 
challenges in APL biology and treatment. 
The first report on APL traces back to 1957, when 
the Norwegian hematologist LK Hillestad recognized 
APL  as  a  distinct  clinical  entity,  whose  “
outstanding  feature  was  its  very  rapidly  dow
course  of  few  weeks’  duration,  a  white  blood  cell 
picture  dominated  by  promyelocytes  and  severe 
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Only a few thousand people worldwide are diagnosed 
each  year  of  Acute  Promyelocytic  Leukemia  (APL). 
However, for a number of reasons, such rare disease is 
regarded as a paradigm in the entire field of medicine. 
Once considered the most malignant human leukemia 
as well as the one associated with the worst prognosis, 
APL has been transformed in the past few decades into 
the  most  frequently  curable  one.  This  extraordinary 
progress  has  been  the  result  of  an  unprecedented 
coincidence of advances in both biological and clinical 
research.  Today,  APL  represents  a  model  for  i) 
differentiation therapy, ii) tailored treatment targeting a 
molecular  aberration,  iii)  value  of  minimal  residual 
disease assessment as a surrogate of clinical outcome, 
earch  in  general.  In  the 
following  pages  are  reviewed  the  major  discoveries 
and  achievements  in  APL biology and  therapy, with 
particular emphasis on those that have had more direct 
an  impact  in  patient  outcome.  Finally,  we  briefly 
ved  issues  and  future 
challenges in APL biology and treatment. 
The first report on APL traces back to 1957, when 
the Norwegian hematologist LK Hillestad recognized 
APL  as  a  distinct  clinical  entity,  whose  “most 
outstanding  feature  was  its  very  rapidly  downhill 
course  of  few  weeks’  duration,  a  white  blood  cell 
picture  dominated  by  promyelocytes  and  severe 
bleeding  caused  mainly  by  fibrinolysis
detailed  account  of  APL  was  given  in  1959  by  J 
Bernard (Hôpital St. Louis, Paris) who reported a series 
of 20 patients with the full definition of the disease and 
its association with promyelocytic proliferation, hyper
acute onset and catastrophic hemorrhagic events.
Since  the  earlier  reports,  the  life
coagulopathy was recognized as the defining 
feature of APL accounting for the majority of deaths at 
presentation  and  during  initial  cytotoxic  treatment, 
with  most  fatal  events  being  intracranial  and 
pulmonary hemorrhages. The hemostatic abnormalities 
were  attributed  to  a  disseminated  intrav
coagulopathy  in  which  fibrinolysis  and  procoagulant 
activity triggered by APL blasts played a major role. 
As  described  by  Rand  et  al
resulted in the resolution of the coagulopathy. 
worth noting that, despite the impre
in  outcome  achieved  after  the  advent  of 
retinoic acid (ATRA, see below) the early death rate in 
APL  has  remained  elevated  even  in  recent  years, 
mostly because many patients die even before they can 
start  treatment.
4,5,6 This 
importance of early recognition of the disease in order 
to  promptly  start  anti
simultaneous transfusion support.
A seminal contribution in APL treatment was made 
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1 A  more 
detailed  account  of  APL  was  given  in  1959  by  J 
Bernard (Hôpital St. Louis, Paris) who reported a series 
f 20 patients with the full definition of the disease and 
its association with promyelocytic proliferation, hyper-
acute onset and catastrophic hemorrhagic events.
2
Since  the  earlier  reports,  the  life-threatening 
coagulopathy was recognized as the defining clinical 
feature of APL accounting for the majority of deaths at 
presentation  and  during  initial  cytotoxic  treatment, 
with  most  fatal  events  being  intracranial  and 
pulmonary hemorrhages. The hemostatic abnormalities 
were  attributed  to  a  disseminated  intravascular 
coagulopathy  in  which  fibrinolysis  and  procoagulant 
activity triggered by APL blasts played a major role. 
et  al,  hematologic  remission 
resulted in the resolution of the coagulopathy. 
3 It is 
worth noting that, despite the impressive improvement 
in  outcome  achieved  after  the  advent  of  All-trans 
retinoic acid (ATRA, see below) the early death rate in 
APL  has  remained  elevated  even  in  recent  years, 
mostly because many patients die even before they can 
This  further  highlights  the 
importance of early recognition of the disease in order 
to  promptly  start  anti-leukemic  therapy  and 
simultaneous transfusion support.
A seminal contribution in APL treatment was made Mediterr J Hematol Infect Dis 2011; 3: Open Journal System
in the early ‘70s, again by J Bernard and co-workers, 
who reported a dramatic raise in complete remission 
(CR) rates from 13% to 57% when using daunorubicin 
as  monochemotherapy.
7 Following  this  landmark 
study,  anthracycline-based  regimens  were  adopted in 
Italy, Spain and France during the ‘70s and ‘80s. APL 
was  indeed  recognized  as  a  distinct  entity  in  these 
countries  long  before  the  advent  of  ATRA  and 
differentiation therapy, whereas in all other countries, 
including the USA, the disease was treated like the rest 
of  AMLs  until  the  early  ‘90s,  that  is,  without  any 
specific  distinction.    Still  nowadays,  while  novel 
experimental  treatments  are  being  tested  and  other 
agents  have  been  shown  to  have  high  anti-leukemic 
activity  in  APL  (e.g.  arsenic  trioxide,  anti-CD33 
antibodies),  the  standard  recommended  treatment  for 
newly  diagnosed  APL  consists  of  anthracycline 
monochemotherapy and ATRA.
8,9 No other myeloid or 
lymphoid  acute  leukemia  shows  a  similar  pattern  of 
chemosensitivity  to  a  single  agent,  and,  in  fact,  
polychemotherapy schemes are the standard treatment
in all non-APL acute leukemias. The biological reasons 
underlying  such  striking  sensitivity  of  APL  to 
anthracycline have not been clarified and should be a 
matter of investigation. Avvisati et al. reported in 1990 
similarly  high  CR  rates  using  idarubicin  instead  of 
daunorubicin.
10
The French-American-British classification of 1976 
clearly  recognized  APL  (M3  type)  and  its  peculiar 
morphologic  features:  these  included  marrow 
infiltration  by  dysplastic  promyelocytes  with  heavy 
granulations  and  sometimes  bundles  of  Auer  rods 
("faggots") accompanied by a strong myeloperoxidase 
(MPO) staining in the cytoplasm.
11 Few years later, a 
microgranular  variant  (M3v)  of  the  disease  was 
identified  and  recognized  in  the  updated  FAB 
classification.
12 This variant accounts for 20% of cases 
approximately.  Subsequent  biologic  studies  showed 
that  compared  to  the  more  common  hypergranular 
form,  the  M3v  subtype  carries  identical  molecular 
features,  while  phenotypically  it  is  characterized  by 
more  frequent  hyperleucocytosis  and  expression  of 
CD2.
13 Importantly,  the  variant  form  is  equally 
responsive  to  anthracyclines,  ATRA  and  arsenic 
trioxide  (ATO),  indicating  that  molecular  identity 
corresponds to equal drug sensitivity in the two forms. 
At  the  biological  level,  a  major  breakthrough  in 
APL  was  the  description  by  J  Rowley  from  the 
University  of  Chicago  of  a  reciprocal  balanced 
translocation between chromosomes 15 and 17 t(15:17) 
(q21;q22).
14 Subsequent  studies  showed  that  this 
translocation  occurs  in  approximately  95%  of  APL 
cases and is unique to the disease. Karyotypic studies 
were pivotal to define APL as a genetic-clinical entity 
and  paved the  way  for  molecular  characterization  of 
the disease.
Despite  the  significant  improvement  in  outcome 
obtained with anthracycline-based chemotherapy, cure 
rates were still between 25 and 50% up to the early 
‘90s. An increase in CR rates was however achieved in 
the late ‘80s with the generalized adoption of intensive 
transfusion  support  (platelets  and  plasma)  during 
induction therapy.
In the mid ‘80s a series of unrelated circumstances 
led to the first experiences with retinoic acid in China 
that brought about a revolutionary approach to cancer 
treatment.  The inspiring inputs to initiate this novel 
strategy derived from i) in vitro studies on leukemic 
cell differentiation; ii) a philosophical lesson derived 
from Confucius who believed in the rehabilitation of 
criminals,  and  iii)  a  need  of  anticancer  drugs  less 
expensive  than  chemotherapy  due  to  the  economic 
constraints  experienced  at  that  time  in China.  The 
unusual  combined  results  of  experimental  evidence, 
philosophical  tradition  and  political-economic 
circumstances  led  to  the  first  attempts  in  medicinal 
treatment  to  convert  criminals  (leukemic  blasts)  into 
good citizens (mature white blood cells) through the 
differentiating agent ATRA. 
The  first  clinical  experience  with  ATRA  was 
reported in 1988 at the Shangai Rui-Jin Hospital under 
the guidance of ZY Wang. Twenty-four APL patients, 
of whom 8 previously treated and 16 newly diagnosed, 
were administered ATRA (45 to 100 mg/mq) as single 
agent  therapy.  Twenty-three  patients  achieved  CR 
without  exacerbation  of  coagulopathy  and  with no 
signs  of  myelosuppression.
15 For  the  first  time  in 
anticancer  therapy  a  dogma  had  been  demolished  –
namely, the belief that a tumor always represents an 
irreversible condition. Notably, no information on the 
retinoic  acid  receptor  being  involved  in  the t(15:17) 
was available at that time. In other words, the use of 
ATRA preceded the cloning of retinoic acid receptor 
alpha and was therefore not driven by knowledge of 
the specific molecular defect affecting APL blasts.  
The  meeting  that  took  place  in  1985  in  Paris 
between Shanghai’s scientists guided by ZY Wang and 
L  Degos  from  the  Hôpital  St  Louis  allowed  the 
beginning of a close collaboration between these two 
groups  and  facilitated  the  introduction  of  ATRA  in 
Western  countries.  A  student  of  Dr.  ZY  Wang’s,  Z 
Chen, was carrying out his PhD at the Hôpital St Louis 
at the time. The striking results obtained in Shanghai 
were reproduced in France on a series of patients in 
first or successive relapse after chemotherapy, with CR 
rates of up to 63% and confirmed worldwide in larger 
cohorts of APL patients.
16,8 Henceforth, Z Chen was 
involved, along with his wife Sai Juan, in biological 
and  clinical  studies  of  APL.  They  have  since 
contributed to the scientific world a number of seminal Mediterr J Hematol Infect Dis 2011; 3: Open Journal System
studies  on  APL  molecular  pathogenesis,  biologic 
characterization and treatment with ATRA and ATO. 
In 2003, Z Chen was appointed member of the USA 
National Academy of Sciences and since 2007 he has 
occupied the post of Chinese Minister of Health. 
In vitro and in vivo studies carried out by R Warrell 
et  al at  Memorial  Sloan-Kettering  Hospital  in  New 
York  showed  that  administration  of  ATRA  at 
pharmacological  concentrations  (10
-6 M)  induced 
morphological maturation of leukemic cells, leading to 
complete  remission.  The  differentiation  process  was 
characterized by the appearance of cells in intermediate 
stages  of  maturation  expressing  both  immature  and 
mature  surface  antigens  (shown  by  flow  cytometry)  
together  with  the  t(15;17)  as  proven  by  sequential 
FISH analysis of primary cells from patients receiving 
ATRA.
17
The  molecular  bases  of  ATRA  response  in  APL 
were unraveled by genetic studies reported in the early 
‘90s. The investigation results concomitantly published 
by three independent groups (coordinated by de H Thé, 
E  Solomon  and  PG  Pelicci,  respectively)  reported 
cloning  of  the  t(15;17)  translocation.
18,19,20 The 
breakpoint on 17q21 was located within the locus of 
the  Retinoic Acid Receptor alpha (RARA) gene. The 
partner  gene  located  in  the  breakpoint  region  on 
chromosome  15q22, originally  named  MYL,  was  a 
previously  unknown  gene  later  on  renamed 
Promyelocytic Leukemia gene or PML. This gene was 
subsequently shown to  be involved in the  control  of 
cell  proliferation,  apoptosis  and  senescence.
21 The 
availability  of  in  vitro (NB4  cell  line)  and  in  vivo
(transgenic mouse) models harboring the PML-RARA
fusion  gene  fostered  investigation  on  APL 
leukemogenesis. In particular, the work carried out by 
PP Pandolfi, PG Pelicci and RM Evans allowed for the 
unraveling  of  the  biochemical  mechanisms  of 
transcriptional repression induced by the PML/RARA 
protein  as well  as  the  molecular  basis  of  ATRA 
response.
22,23,24 Meanwhile, the cloning of the t(15;17) 
also enabled the design of PCR-based strategies to be 
used  for  rapid  diagnosis  as  well  as  for  sensitive 
detection of minimal residual disease.
25,26,27
At the clinical level, it soon became clear that the 
outstanding results  obtained with  ATRA  in  terms of 
CR rates were not paralleled by satisfactory outcomes 
in the long-term. This led to the design of ATRA plus 
chemotherapy trials that were conducted in Europe, the 
USA and Japan by multicenter cooperative groups. The 
results of these studies, which were recently updated 
on  a  very  long-term  follow-up,  indicate  that  the 
simultaneous  use  of  ATRA  and  anthracycline-
containing chemotherapy is  the best option as it can 
cure up to 75%-80% of newly diagnosed patients.
8,9 A 
consensus  based  on  these  studies  established 
simultaneous  administration  of  ATRA  plus 
chemotherapy as the gold standard in frontline therapy 
of APL. 
Meanwhile,  the  amplification  of  PML-RARA 
fusion transcript by RT-PCR approach provided high 
sensitivity  and  specificity  for  rapid  and  reliable 
diagnostic  results  and  enabled  the  detection  of  the 
precise type of breakpoint on the PML gene so as to 
better  assess  minimal  residual  disease  (MRD).  The 
clinical importance of PCR-based diagnosis and MRD 
monitoring in APL was initially suggested by studies 
carried out in the US and in Italy.
25,26 These showed 
that persistence or reappearance of PCR positivity for 
PML/RARA in patients with morphological remission 
was  correlated to  impending  hematological  relapse.
25
Subsequent  observations  on  the  same  line  were 
reported in  England by D  Grimwade and by several 
other  investigators  worldwide.
27,28 The  body  of 
information  on  outcome  correlation  derived  from 
longitudinal PCR studies in the context of clinical trials 
offered  the  possibility  to  identify  patients  requiring 
treatment intensification and to adopt  “pre-emptive” 
therapeutic strategies in Italy and the UK.
29,30 Notably, 
this  approach  proved  useful  in  avoiding  early 
hemorrhagic deaths  at  time  of  relapse  and improved 
overall outcome. The recent adoption of modern real-
time  quantitative  PCR  for  PML/RARA  detection 
allowed  for  better  investigation  of  the  kinetics  of 
response and disease relapse as well as establishing a 
rationale for sample collection timing, as shown in a 
large study from the MRC reported by Grimwade et 
al.
30
The  trials  conducted  in  the  1990-2000  decade 
provided an important source for the investigation of 
prognostic  factors  to  be  used  for  treatment 
stratification. In particular, the so-called Sanz’s score 
was  developed  to  dissect  relapse  risks  for  patients 
receiving  AIDA-like  regimens  adopted  by  the 
GIMEMA and PETHEMA.
31 This in turn allowed the 
design  of  distinct  strategies  which  were  aimed  at 
sparing  unnecessary  toxicity  for  patients  with  WBC 
counts  inferior  to  10x10
9/L,  whereas  more  intensive 
post-induction  chemotherapy  including  cytarabine 
were adopted for high risk (hyperleucocytic) patients. 
The results of both GIMEMA and PETHEMA studies 
using  a  risk-adapted  approach  showed  significant 
improvement  of  outcome.
32,33 Interestingly  enough, 
ever since the early times of APL history, J Bernard 
identified fibrinogen levels and  WBC  count  as    two 
important prognostic factors in APL.
34
Other  large  trials  conducted  by  the  French-
European APL Group, the British MRC (now NCRI), 
the  Japanese  JALSG  and  the  German  AMLCG 
confirmed  the  advantage  of  risk-adapted  strategies 
using  mainly  WBC  count  as  a  prognostic  factor. Mediterr J Hematol Infect Dis 2011; 3: Open Journal System
Overall,  studies  reported  in  the  last  few  years  with 
ATRA and risk-adapted chemotherapy resulted in CR 
rates of up to 95% and OS rates >85%.
8,9,35
In  summary,  a  number  of  significant  advances 
contributed to achieve the extraordinary cure rates in 
APL  mentioned  above,  converting  this  once  rapidly 
fatal leukemia into the most curable one. The advances 
can be chronologically summarized as such: i) Advent 
of ATRA and its inclusion in front-line combinatorial 
treatments  together  with  anthracycline-based 
chemotherapy; ii) Improvements in supportive care; iii) 
Diagnostic  molecular  refinement  and  sensitive  MRD 
monitoring  by  PCR;  iv)  Definition  of  relapse-risk
categories and adoption of risk-adapted strategies, and 
v) Pre-emptive therapy of disease relapse. 
In  spite  of  such  impressive  progress,  new 
revolutionary facts were yet to come.
In 1994, J Bernard described the history of APL as 
a  series  of  battles  to  combat  dogmas.  This 
extraordinary  man  indeed  promoted,  anticipated  and 
witnessed many revolutionary achievements in APL’s 
history.  Despite  his  long life,  he died  shortly before 
one last dogma was about to be demolished. The recent 
advent of an old revisited remedy, arsenic, as the most 
effective single agent in APL, brought up the potential 
to cure leukemia without chemotherapy.
Arsenic  compounds  had  been  used  as  therapeutic 
agents  for  more  than  2,000  years  in  Western  and 
Eastern medicine, particularly in China. The efficacy 
of  arsenic  as  an  anti-leukemic  agent  was  initially 
demonstrated  in  Boston  in  1880s  when  an  arsenic 
solution  was  used  to  reduce  leucocytosis.  Half  a 
century later, arsenic proved to be effective in Chronic 
Myeloid Leukemia and was widely used to treat this 
condition  before  the  introduction  of  standard 
chemotherapy. Despite the advent of novel cytotoxic 
drugs, the empirical use of arsenic as an anti-leukemic 
agent continued in China throughout the past century. 
Initial  results  on  APL  treatment  with  ATO  were 
published in the late ’90s by Chinese investigators who 
observed  striking  responsiveness  only  in  this  subset 
among several leukemia types assessed. In particular, a 
study  from  Harbin  Medical  University  reported  CR 
rates with ATO as a single agent of up to 73% and 50% 
in  newly  diagnosed  and  relapsed  APL  patients 
respectively.  Similar  results  were  published  by 
investigators from Shanghai in a series of APL patients 
in relapse after first-line treatment with ATRA.
36,37
These preliminary results encouraged the design of 
a  multicenter  trial  in  the  US  in  which  ATO  was 
administered as salvage therapy in relapsed patients. 
Eighty-five  percent  of  the  40  patients  treated  with 
single agent ATO achieved hematological CR and 86% 
of the assessable patients achieved molecular complete 
remission  after  consolidation  cycles.
38 A  number  of 
subsequent studies conducted in Europe, India and Iran 
confirmed these observations and encouraged the use 
of  ATO  as  first  line  therapy  in  light  of  its  efficacy 
coupled with a mild toxicity profile.
39
Meanwhile,  several  groups  investigated  the 
molecular mechanism underlying the efficacy of ATO 
in  APL. These studies showed a dual  mechanism of 
action  inducing  partial  differentiation  at  low 
concentrations  and  a  pro-apoptotic  effect  at  higher 
doses. As demonstrated by Chen et al and Shao et al, at 
low concentrations, ATO exerts a partial differentiating 
effect  by  inducing  the  sumoylation  of  both  PML-
RARA and PML, leading to their degradation through 
the  proteasome  pathway.  On  the  contrary,  at  high 
concentrations ATO induces apoptosis through caspase 
activation,  ROS  production  and  induction  of  the 
mithocondria-mediated intrinsic apoptotic pathway.
40,41
Shen et al and Hu et al reported that, compared to 
ATRA  alone,  the  ATO  plus  ATRA  combination 
resulted  in  earlier  CR  achievement  and  platelet 
recovery,  more  rapid  reduction  of  the  PML-RARA 
transcript and lower relapse rates in newly diagnosed 
APL  patients.
42,43 Similar  results  were  reported  by 
Estey et al from the MD Anderson Cancer Center in 
Houston.
44 Finally,  a  recently  terminated  large 
randomized  trial  conducted  in  the  USA,  showed  a 
benefit  from  adding  ATO  to  standard  ATRA  and 
chemotherapy  during  consolidation  in  front-line 
therapy.
45
The suggested synergism of the ATRA plus ATO 
combination  was  exploited  in  the  design  of  two 
prospective  randomized  studies  in  newly  diagnosed 
patients  that  are  currently  being  carried  out  by  the 
Italian-German  groups  GIMEMA-SAL-ALSG 
(APL0406 study) as well as by the British NCRI. In 
both  cases,  a  totally  chemotherapy-free  approach 
(experimental arm) is being tested against the standard 
AIDA-like regimen. In particular, the Italian-German 
study investigates  in the experimental arm the efficacy 
of the prolonged ATO+ATRA scheme developed by E 
Estey  et  al
44 together  with  longitudinal  PCR-
monitoring as a safety criterion to adopt pre-emptive 
salvage for patients who undergo molecular relapse. It 
is expected that the results of these randomized studies 
will better clarify whether APL can be cured without 
chemotherapy.
Although,  after  half  a  century  of  revolutionary 
events  in  biological  and  clinical  research  APL  has 
become  the  most  curable  of  acute  leukemias,  many 
challenges remain for investigation and several issues 
are still unsolved. In addition, both in developing and 
developed  parts  of  the  world  many  patients  still  die 
before  treatment  or  during  the  first  days  after  the 
initiation of therapy. Improvements in early death rate 
require  a  number  of  efforts  in  education  on  disease Mediterr J Hematol Infect Dis 2011; 3: Open Journal System
characteristics, epidemiologic studies using population 
registries as well as investigation on the coagulopathy 
and predictive factors of major hemorrhagic events.          
Despite the promise of differentiation therapy, more 
than 20 years after the advent of ATRA we have not 
been able to extend this approach beyond APL and no 
differentiation therapy has been successfully applied to 
other  leukemia  subsets  or  solid  tumors.  This 
underscores our limited understanding of the molecular 
mechanisms underlying leukemic cell differentiation in
response  to  retinoids.  Similarly,  the  mechanism  of 
action of ATO is not fully deciphered. 
In  conclusion,  as  a  model  disease  that  has 
continuously  inspired  investigation  generating 
important  insights,  it  can  be  said  that  APL’s  future 
history may still have novel unexpected discoveries in 
store  and  so  add  new  thrilling  chapters  to  this 
revolutionary tale.     
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